Drug intelligence / Profile preview

N-P27

Development stage: Preclinical
Lead developer: Neurocarrus
Modality: Recombinant Proteins and Enzymes

Overview

N-P27 is an engineered recombinant protein biologic being developed by Neurocarrus for the treatment of Alzheimer's disease. Described as a "plaque buster," the drug is designed to actively break down and dissolve established amyloid-beta plaques in the brain, a mechanism intended to reduce the pathological burden of the disease more effectively than therapies that only prevent plaque formation. N-P27 is currently in the preclinical stage of development.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on N-P27.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-P27.

Explore the full profile